Table 4.
Associations of cell phone use daily use hour on the risk of thyroid cancer in populations stratified by SNP variants
| Gene | SNP | Cell phone non-user |
Daily use hour |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤1 hour/day |
>1 hour/day |
P value for trend | |||||||||
| Case | Control | ORa (95% CI) | Case | Control | ORa (95% CI) | Case | Control | ORa (95% CI) | |||
| PAK6 | rs11070256 | ||||||||||
| AA | 33 | 59 | 1.00 | 73 | 88 | 0.66 (0.38–1.14) | 71 | 61 | 0.91 (0.51–1.62) | 0.8862 | |
| AC/CC | 11 | 53 | 1.00 | 48 | 41 | 2.67 (1.31–5.42) | 44 | 33 | 3.01 (1.44–6.30) | 0.0041 | |
| MDM2 | rs1695147 | ||||||||||
| AA | 31 | 69 | 1.00 | 71 | 92 | 0.78 (0.47–1.30) | 73 | 60 | 1.18 (0.69–2.02) | 0.5074 | |
| AC/CC | 13 | 43 | 1.00 | 50 | 37 | 2.76 (1.26–6.06) | 41 | 34 | 2.86 (1.30–6.32) | 0.0156 | |
| HDAC4 | rs6732673 | ||||||||||
| TT | 20 | 33 | 1.00 | 43 | 48 | 0.61 (0.29–1.28) | 40 | 32 | 1.08 (0.50–2.36) | 0.7358 | |
| TC/CC | 24 | 80 | 1.00 | 76 | 80 | 1.63 (0.95–2.78) | 74 | 62 | 2.00 (1.15–3.46) | 0.0154 | |
| HDAC4 | rs1063639 | ||||||||||
| GG | 13 | 14 | 1.00 | 27 | 35 | 0.25 (0.06–1.02) | 26 | 20 | 0.54 (0.19–1.54) | 0.3825 | |
| GA/AA | 31 | 98 | 1.00 | 94 | 94 | 1.63 (1.01–2.65) | 89 | 73 | 1.94 (1.18–3.18) | 0.0106 | |
| HDAC4 | rs843458 | ||||||||||
| AA | 25 | 73 | 1.00 | 41 | 46 | 0.88 (0.44, 1.75) | 26 | 36 | 0.85 (0.40, 1.81) | 0.6847 | |
| AC/CC | 19 | 40 | 1.00 | 79 | 83 | 1.53 (0.89, 2.63) | 89 | 58 | 2.28 (1.09, 4.77) | 0.1024 | |
| GATA4 | rs3757949 | ||||||||||
| GG | 19 | 78 | 1.00 | 48 | 64 | 0.62 (0.32, 1.20) | 45 | 37 | 0.89 (0.43, 1.85) | 0.2846 | |
| GC/CC | 24 | 35 | 1.00 | 71 | 63 | 1.90 (0.90, 4.01) | 69 | 57 | 2.25 (1.28, 3.96) | 0.0853 | |
| UBE2V1 | rs6125888 | ||||||||||
| TT | 34 | 100 | 1.00 | 18 | 30 | 0.68 (0.42, 1.10) | 21 | 25 | 0.45 (0.16, 1.23) | 0.2951 | |
| TG/GG | 10 | 13 | 1.00 | 102 | 98 | 1.59 (0.95, 2.66) | 94 | 69 | 1.89 (0.91, 3.93) | 0.1231 | |
| LINC00336 | rs396746 | ||||||||||
| AA | 35 | 82 | 1.00 | 83 | 105 | 0.80 (0.50–1.30) | 87 | 73 | 1.23 (0.75–2.02) | 0.3380 | |
| AC/CC | 9 | 31 | 1.00 | 38 | 24 | 4.15 (1.57–11.0) | 28 | 21 | 3.31 (1.21–9.12) | 0.1044 | |
| DACT2 | rs12204529 | ||||||||||
| CC | 36 | 72 | 1.00 | 80 | 92 | 0.75 (0.45–1.25) | 80 | 67 | 1.13 (0.67–1.89) | 0.5611 | |
| CG/GG | 8 | 40 | 1.00 | 41 | 37 | 3.11 (1.38–7.00) | 34 | 27 | 3.37 (1.42–8.03) | 0.0074 | |
| DACT2 | rs3800537 | ||||||||||
| AA | 38 | 75 | 1.00 | 82 | 91 | 0.82 (0.50–1.36) | 83 | 68 | 1.17 (0.70–1.96) | 0.4758 | |
| AG/GG | 6 | 38 | 1.00 | 39 | 38 | 2.93 (1.28–6.72) | 32 | 26 | 3.38 (1.39–8.22) | 0.0088 | |
a
adjusted for age (continuous), sex (male, female), education (<college, college, >college), family history of thyroid cancer (yes, no), alcohol consumption (yes, no), body mass index (BMI, <25, 25–29.9, ≥30), and previous benign thyroid diseases (yes, no).